Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921818 | 0.98 | TSHR (0.97) | TSHRKMT2ACYP3A4L3MBTL1MEN1 | |
| SCHEMBL4716406 | 0.88 | TSHR (0.78) | TSHRKMT2ACYP3A4MEN1HSD17B10 | |
| SCHEMBL3919968 | 0.85 | TSHR (0.74) | TSHRKMT2AL3MBTL1MEN1ALDH1A1 | |
| SCHEMBL4713654 | 0.85 | TSHR (0.74) | TSHRKMT2ACYP3A4L3MBTL1MEN1 | |
| SCHEMBL11181898 | 0.85 | TSHR (0.74) | TSHRKMT2ACYP3A4L3MBTL1MEN1 | |
| SCHEMBL396705 | 0.85 | KMT2A (0.77) | TSHRKMT2AL3MBTL1MEN1HSD17B10 | |
| SCHEMBL1000486 | 0.85 | POLB (0.74) | TSHRKMT2ACYP3A4MEN1HSD17B10 | |
| SCHEMBL395198 | 0.84 | KMT2A (0.75) | TSHRKMT2AL3MBTL1MEN1HSD17B10 | |
| SCHEMBL11177270 | 0.84 | TSHR (0.72) | TSHRKMT2ACYP3A4L3MBTL1MEN1 | |
| SCHEMBL4717672 | 0.84 | TSHR (0.72) | TSHRKMT2ACYP3A4MEN1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | claimed |
| EP-1615904-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2006-01-18 | — | — | EP | claimed |
| WO-2004092135-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA (SE) | 2004-10-28 | — | — | WO | claimed |
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8367661-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232092-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. | 2012-09-13 | — | — | US | disclosed |
| US-8202859-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20120088779-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8101620-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110112154-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2011-05-12 | — | — | US | disclosed |
| EP-1615904-B1 | SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070021606-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| EP-1615904-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092135-A2 | SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS | ASTRAZENECA (SE) | 2004-10-28 | — | — | WO | disclosed |
| EP-0556673-B1 | Ortho-substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as medicaments containing them | HOECHST AG (DE) | 1997-09-17 | — | — | EP | disclosed |
| EP-0556673-A1 | Ortho-substituted benzoylguanidines for the treatment and prophylaxis of heart-rhythm disorders and ischaemically induced damage, as well as inhibition of cell proliferation | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | TSHR 3581/4885KMT2A 2395/4885CYP3A4 4735/4885 |
| US-20120232092-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | TSHR 3581/4885KMT2A 2395/4885CYP3A4 4735/4885 |
| US-20110112154-A1 | Compounds, compositions and methods | TNNI3, TNNT2, MYLK2 | TSHR 4440/4885KMT2A 3413/4885CYP3A4 4605/4885 |
| US-20070021606-A1 | Therapeutic compounds | GRIN1, GRIN3A, GRM2 | TSHR 685/4885KMT2A 3726/4885CYP3A4 3976/4885 |
| US-20120088779-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | TSHR 3581/4885KMT2A 2395/4885CYP3A4 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.